Stock Appreciation Right

(redirected from SARS)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Stock Appreciation Right (SAR)

A contractual right, often granted in tandem with an option that allows an individual to receive cash or stock of a value equal to the appreciation of the stock from the grant date to the date the SAR is exercised.

Stock Appreciation Right

A bonus that an employer pays an employee equal to the price appreciation on the company's stock over a given period of time. This is much like an employee stock option. The primary difference is that the employee does not have to actually buy stock; that is, he/she does not have to pay anything. Rather, the employee simply receives the cash or stock bonus in the specified amount.

stock appreciation right

Executive compensation that permits an employee to receive cash or stock equal to the amount by which the firm's stock price exceeds a specified base price.
References in periodicals archive ?
In conclusion, viremia appears to be a consistent feature in both pediatric and adult SARS patients.
While congratulating China's SARS efforts, World Health Organization Western Pacific Director Shigeru Omi complained in late June that before Beijing's ''political commitment'' to tell the truth about the spread of SARS, its information sharing was ''not prompt and transparent.
Bush has signed an executive order triggering a World War I-era law that lets him add SARS to the ranks of such diseases as cholera, smallpox, and the plague.
Canadian officials took very aggressive action to limit the spread after several people, including health care workers, became ill after caring for SARS patients or working in SARS hospitals.
The SARS story has provided an opportunity to employ the same deft touch.
1%; and Goldman Sachs estimated that SARS could take 0.
Although SARS is the most recent example of an emerging disease for which quarantine was implemented, the potential for household transmission through pets should be considered in any new disease when information is incomplete regarding potential hosts and the risk for interspecies transmission.
A respiratory virus is really the ideal route for a SARS vaccine," says Collins.
An outbreak of an unusual pneumonia was first reported in the Guandong Province of China in November 2002, but wasn't recognized as SARS until March when cases began to be reported in Hong Kong and Vietnam, according to the New York City Department of Health-and Mental Hygiene.
In the early stages of SARS, patients experience fever, cough, muscle ache, and difficulty breathing.
In modern times, the most extensive use of nonpharmaceutical public health interventions to contain a transmissible respiratory viral infection occurred during the SARS epidemic of 2003.
Immunologist Andrea Gambotto and his colleagues at the University of Pittsburgh School of Medicine devised a vaccine using three common-cold adenoviruses, each genetically modified to produce a protein from the coronavirus that causes SARS.